ライフサイエンスコーパス: radioiodine

1 atment of patients with hyperthyroidism with radioiodine.

2 a from a thyroid cancer patient treated with radioiodine.

3 stered intramuscularly prior to testing with radioiodine.

4 prescription of the administered activity of radioiodine.

5 toxicity to normal tissues from therapeutic radioiodine.

6 efficacy of the subsequent ablation dose of radioiodine.

7 er the ability to treat prostate cancer with radioiodine.

8 d for long-term vigilance in those receiving radioiodine.

9 step toward therapy of prostate cancer with radioiodine.

10 etween 0.5 and 120 h after administration of radioiodine.

11 deposition patterns between radiocesium and radioiodine.

12 ine-avid and can be effectively treated with radioiodine.

13 scintigraphic images reflects uptake of free radioiodine.

14 ed therapeutics alone or in combination with radioiodine.

15 sis for a personalized approach for adjuvant radioiodine.

16 It is not known whether low-dose radioiodine (1.1 GBq [30 mCi]) is as effective as high-d

17 The radioiodines 123I, 124I, 125I and 131I were accommodated

18 se of recombinant human thyrotropin) and two radioiodine ((131)I) doses (i.e., administered activitie

19 these, 59 patients had negative findings on radioiodine (131I) whole-body scintigraphy (WBS).

20 1 GBq [30 mCi]) is as effective as high-dose radioiodine (3.7 GBq [100 mCi]) for treating patients wi

21 Of the 8 patients treated with radioiodine, 5 had confirmed partial responses and 3 had

22 otropin and low-dose (1.1 GBq) postoperative radioiodine ablation may be sufficient for the managemen

23 to accumulate iodide provides the basis for radioiodine ablation of differentiated thyroid cancers a

24 Thyrogen-assisted diagnosis and radioiodine ablation of thyroid remnant provide a reliab

25 and function is affected after high-activity radioiodine ablation therapy in patients with DTC.

26 a 185-MBq (5 mCi) dose of (131)I 72 h before radioiodine ablation without concern for thyroid stunnin

27 After total thyroidectomy followed by radioiodine ablation, 61 consecutive patients with eleva

28 After thyroidectomy and radioiodine ablation, thyroglobulin becomes a sensitive

29 Therefore, we investigated radioiodine accumulation and therapeutic effectiveness o

30 prostate-specific promoters induces generous radioiodine accumulation in prostate cancer cells that m

31 In the approach of fixed radioiodine activity (3.0 +/- 1.0 GBq), 89% of thyroid r

32 Higher levels of radioiodine activity also were observed in kidney when L

33 Thyroid ablation was assessed 8 months after radioiodine administration by neck ultrasonography and m

34 h water, but in contrast allows placement of radioiodine and the photoactive moieties within the same

35 novirus serotypes 2 and 12 were labeled with radioiodine and then injected into the bloodstreams of m

36 ignificant improvement in tumor retention of radioiodine and tumor:normal tissue ratios was seen when

37 and transgene expression before therapeutic radioiodine application.

38 Using iodine/radioiodine as a surrogate for the radiohalogen (211)At,

39 microsomes and uptake of the resultant free radioiodine by Na/I symporters in the gastric mucosa.

40 Higher ex vivo radioiodine counts were noted in the hearts perfused wit

41 The geochemical transport and fate of radioiodine depends largely on its chemical speciation t

42 used on better patient selection and reduced radioiodine doses for remnant ablation.

43 ority trial comparing low-dose and high-dose radioiodine, each in combination with either thyrotropin

44 ted thyroid cancer or whether the effects of radioiodine (especially at a low dose) are influenced by

45 ne-glycine-aspartic acid peptide ligands and radioiodine, exhibited high-affinity/avidity binding, fa

46 Nevada Test Site (1951-1992) has resulted in radioiodine exposure for nearby populations.

47 Our findings suggest that childhood radioiodine exposure from nuclear testing may be related

48 e is known regarding the effect of childhood radioiodine exposure on subsequent fertility.

49 though the long-term effect of environmental radioiodine exposure on thyroid disease has been well st

50 young patients exposed to the post-Chernobyl radioiodine fallout at very young age and a matched none

51 arcinoma (PTC) among children exposed to the radioiodine fallout has been one of the main consequence

52 We find that radioiodine fallout is actively and efficiently scavenge

53 ions of GO in American patients treated with radioiodine for hyperthyroidism.

54 dence and mortality in patients treated with radioiodine for hyperthyroidism.

55 Dissociation of radioiodine from the antibody during metabolism has been

56 es have shown that rapid clearance of excess radioiodine from the body in the euthyroid state with Th

57 Radioiodine has been shown to reduce recurrences and imp

58 evated serum thyroglobulin and both negative radioiodine imaging and negative (18)F-FDG PET/CT.

59 this paper addresses the role of preablation radioiodine imaging and provides nuclear medicine physic

60 py settings and reviews the impact of fusion radioiodine imaging on staging, risk stratification, and

61 iodide symporter (hNIS), in combination with radioiodine in an orthotopic triple-negative breast canc

62 urs with hypothyroidism stimulates uptake of radioiodine in normal and cancerous thyroid tissues.

63 ARRY-142886) could reverse refractoriness to radioiodine in patients with metastatic thyroid cancer.

64 adioactive plume and the behavior of harmful radioiodine in the atmosphere, long-term precipitation s

65 Analogous to radioiodine in the evaluation of patients with different

66 The elevated levels of radioiodine in the stomach observed in our experiments a

67 via an indirect method attenuated uptake of radioiodine in tissues that express the Na/I symporter w

68 uorous oxidant that can be used to introduce radioiodine into small molecules and proteins and genera

69 tatic thyroid cancers that are refractory to radioiodine (iodine-131) are associated with a poor prog

70 trations to stimulate thyroid tissue so that radioiodine (iodine-131) scanning can be performed.

71 tiated thyroid cancer that was refractory to radioiodine (iodine-131).

72 yperthyroidism with antithyroid drugs alone, radioiodine is increasingly used as first line therapy,

73 ty in those treated for hyperthyroidism with radioiodine is reassuring.

74 Radioiodine is used increasingly as first-line treatment

75 e provide a survey of the use of 2 different radioiodine isotopes for targeting the sodium-iodine sym

76 proach also highlights the impact of altered radioiodine kinetics as seen with recombinant human thyr

77 Low renal retention of the radioiodine label creates a precondition for radionuclid

78 We designed a route to prepare the radioiodine-labeled androgen on microscale through treat

79 . administration; intravenously administered radioiodine-labeled asialoEPO bound to neurons within th

80 or to confer residualizing properties on the radioiodine metabolites.

81 euthyroid with either long-term CBZ (n=3) or radioiodine (n=2).

82 in the case of negative (18)F-FDG PET/CT in radioiodine-negative DTC patients with elevated and risi

83 trast-enhanced, full-dose) in 15 consecutive radioiodine-negative DTC patients with elevated and risi

84 Patients who are thyroglobulin-positive but radioiodine-negative or who have antithyroglobulin antib

85 t least one positive scan) were treated with radioiodine on the basis of superior scans done after wi

86 mean age, 16.5 y) were treated with (131)I (radioiodine, or radioactive iodine [RAI]); the median fo

87 us thyrotropin alfa (84.3%) versus high-dose radioiodine plus thyroid hormone withdrawal (87.6%) or h

88 Similar results were found for low-dose radioiodine plus thyrotropin alfa (84.3%) versus high-do

89 roid hormone withdrawal (87.6%) or high-dose radioiodine plus thyrotropin alfa (90.2%).

90 Low-dose radioiodine plus thyrotropin alfa was as effective as hi

91 t or accidental events involving exposure to radioiodines, prophylaxis against malignant disease of t

92 t is not clear whether the administration of radioiodine provides any benefit to patients with low-ri

93 those that are refractory to treatment with radioiodine (RAI), have a high prevalence of BRAF (v-raf

94 wth factor receptor (VEGFR) and approved for radioiodine (RAI)-refractory differentiated thyroid canc

95 r-targeted treatments hold great promise for radioiodine-refractory and surgically inoperable thyroid

96 Patients with radioiodine-refractory cancer have historically had poor

97 ways have been tested in clinical trials for radioiodine-refractory differentiated thyroid cancer (DT

98 rvival (PFS) versus placebo in patients with radioiodine-refractory differentiated thyroid cancer (RR

99 tients with metastatic, rapidly progressive, radioiodine-refractory differentiated thyroid cancers.

100 etastatic differentiated thyroid cancer have radioiodine-refractory disease, based on decreased expre

101 Patients with radioiodine-refractory disease, therefore, are not amena

102 al trials of targeted drugs in patients with radioiodine-refractory disease.

103 ion of (124)I dosimetry in a patient who had radioiodine-refractory thyroid cancer and who underwent

104 in delineating the molecular pathogenesis of radioiodine-refractory thyroid cancer.

105 ospectively assessed a median of 2.5 y after radioiodine remnant ablation (RRA) in 394 consecutive th

106 Radioiodine remnant ablation (RRA) is frequently used af

107 encing and because it cannot be labeled with radioiodine, requiring radiolabeling of the peptide liga

108 progressive, locally advanced or metastatic, radioiodine-resistant differentiated thyroid cancer with

109 dioiodine retention with all of the adducts; radioiodine retention at 45 h was up to 86% greater in c

110 ssing experiments showed marked increases in radioiodine retention with all of the adducts; radioiodi

111 nts with thyroid cancer underwent whole-body radioiodine scanning by two techniques: first after rece

112 of the 127 patients had positive whole-body radioiodine scans by one or both techniques.

113 that were not detected by the corresponding radioiodine scans.

114 aging studies, including CT, ultrasound, and radioiodine scintigraphy (RIS).

115 ing by application of SPECT/CT technology to radioiodine scintigraphy in both diagnostic and post-the

116 Patients staged pN0 received less radioiodine than patients staged pN1 (median 30 vs 100 m

117 , a novel approach for labeling the PNA with radioiodine that avoided solubility issues and poor labe

118 ts with thyroid cancer that is refractory to radioiodine; the effectiveness may be greater in patient

119 In high-activity radioiodine therapies for differentiated thyroid cancer,

120 One patient had received no previous radioiodine therapy and another withdrew consent before

121 ases (BMs) are often resistant after initial radioiodine therapy applying the standard-activity appro

122 eranostic compounds, with a special focus on radioiodine therapy for differentiated thyroid cancer an

123 ting agents in conjunction with TSH-promoted radioiodine therapy for epithelial thyroid cancers.

124 tiated thyroid cancer undergoing their first radioiodine therapy for remnant ablation.

125 ate the delay between ICM administration and radioiodine therapy in patients with differentiated thyr

126 Radioiodine therapy is a routine procedure of treatment

127 ion of the course of disease, and adjunctive radioiodine therapy may all be indicated as were perform

128 gene transfer might offer the possibility of radioiodine therapy of prostate cancer.

129 initial thyroid surgery and the addition of radioiodine therapy or external radiation therapy remain

130 Radioiodine therapy was also associated with improvement

131 In patients with papillary cancer, radioiodine therapy was associated with improvement in c

132 I PET/CT images of 47 patients scheduled for radioiodine therapy were retrospectively analyzed.

133 Radioiodine therapy with (131)I is used for treatment of

134 patients reached the dosimetry threshold for radioiodine therapy, including all 5 patients with NRAS

135 To maximize the effectiveness of radioiodine therapy, patients are first treated by total

136 Before and after initial radioiodine therapy, patients underwent serial PET/CT sc

137 After radioiodine therapy, patients with follicular thyroid ca

138 small cohort of patients undergoing repeated radioiodine therapy, we could not demonstrate alteration

139 toms were insignificantly fewer at 1 y after radioiodine therapy.

140 with thyroid carcinoma at the first ablative radioiodine therapy.

141 ting hormone) (rTSH) to prepare patients for radioiodine therapy.

142 r patients with thyroid carcinoma undergoing radioiodine therapy.

143 d for patients, who had undergone at least 1 radioiodine therapy.

144 ose (AD) to lesions and their response after radioiodine therapy.

145 d analyzed for speciation of radiocesium and radioiodine to explore their chemical behavior and isoto

146 e relative contribution of bound and unbound radioiodine to imaging findings.

147 This correlates with the distances from the radioiodine to the sugars of the corresponding bases in

148 ered 154% (P = .01) and 237% (P = .002) more radioiodine to tumor sites over control antibodies at 24

149 nal methods, BC8 delivered 2- to 4-fold more radioiodine to tumors than 1F5, with tumor-to-normal org

150 ary and follicular thyroid carcinoma, and on radioiodine total-body imaging demonstrated focal, lower

151 erations in salivary gland functioning after radioiodine treatment ((131)I) are scarce.

152 d cancers, and is often followed by adjuvant radioiodine treatment for papillary and follicular types

153 d sialoadenitis are frequent side effects of radioiodine treatment in differentiated thyroid cancer (

154 In most patients, radioiodine treatment is done for ablation of residual t

155 Adjuvant radioiodine treatment may be modulated, however, by surg

156 ferred for a dosimetric study and subsequent radioiodine treatment of focal neck uptake of 131I were

157 We believe that the use of Thyrogen for radioiodine treatment of metastatic thyroid cancer may a

158 pectively assess the effect of high-activity radioiodine treatment on stimulated whole saliva flow ra

159 Radioiodine treatment planning for these patients is usu

160 The patient then received radioiodine treatment with granulocyte colony-stimulatin

161 After radioiodine treatment, no substantial change was seen in

162 dysplastic syndrome more than 51 weeks after radioiodine treatment, with progression to acute leukemi

163 east cancers but at a level insufficient for radioiodine treatment.

164 The patients were followed for 1 y after radioiodine treatment.

165 e significantly impacts upon the efficacy of radioiodine treatment.

166 (AD) of radiation and response after initial radioiodine treatment.

167 -up for DTC patients receiving high-activity radioiodine treatment.

168 va were collected both before and 5 mo after radioiodine treatment.

169 rrelated with saliva flow rate changes after radioiodine treatment.

170 )I PET/CT scans before and after their first radioiodine treatment.

171 Radioactivity from radioiodine, tritium, and uranium is not expected to cre

172 by these cells allowing them to concentrate radioiodine up to 18-fold compared with controls.

173 achieve comparability between pretherapeutic radioiodine uptake (RAIU) measurements by (124)I PET/CT

174 T4 levels, elevated sedimentation rate, low radioiodine uptake and/or nonvisualization on scan and o

175 nfection was confirmed by immunoblotting and radioiodine uptake assays.

176 GLV-1h153 colonization of tumors mediated radioiodine uptake at potentially therapeutic doses.

177 Thyrotropin stimulates radioiodine uptake for scanning in patients with thyroid

178 False-positive radioiodine uptake has been reported in many organ syste

179 iouptake assay showed a 178-fold increase of radioiodine uptake in hNIS-expressing infected cells com

180 for salivary gland dysfunction, and whether radioiodine uptake in salivary glands on diagnostic scan

181 associated with semiquantitatively assessed radioiodine uptake in salivary glands on diagnostic scan

182 Chronological changes in values for thyroid radioiodine uptake measurements (RIU) have been reported

183 Salivary gland radioiodine uptake on diagnostic scans was correlated wi

184 uccessful ablation was defined as no visible radioiodine uptake on the follow-up diagnostic scans, pe

185 inal diagnosis in 28 of 143 cervical foci of radioiodine uptake seen on planar imaging.

186 clinical and clinical data on restoration of radioiodine uptake.

187 s were 85.0% in the group receiving low-dose radioiodine versus 88.9% in the group receiving the high

188 he metastatic lesion or lesions, therapeutic radioiodine was administered while the patient was recei

189 bination therapy with GLV-1h153 and systemic radioiodine was assessed.

190 d human tumor cells efficiently concentrated radioiodine when infected with MV-NIS.

191 ual thyroid tissue after thyroidectomy using radioiodine whole-body (WB) imaging following preparatio

192 ration, prompting efforts to covalently link radioiodine with residualizing molecules.

193 yrotropin alfa was as effective as high-dose radioiodine, with a lower rate of adverse events.

194 Radioiodine within the urinary bladder or, at times, the

195 istration of the smallest possible amount of radioiodine would improve care.